A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Journal of Hepatology, Journal Year: 2023, Volume and Issue: 79(6), P. 1542 - 1556

Published: June 24, 2023

The principal limitations of the terms NAFLD and NASH are reliance on exclusionary confounder use potentially stigmatising language. This study set out to determine if content experts patient advocates were in favour a change nomenclature and/or definition. A modified Delphi process was led by three large pan-national liver associations. consensus defined priori as supermajority (67%) vote. An independent committee external made final recommendation acronym its diagnostic criteria. total 236 panellists from 56 countries participated 4 online surveys 2 hybrid meetings. Response rates across survey rounds 87%, 83%, 78%, respectively. Seventy-four percent respondents felt that current sufficiently flawed consider name change. "nonalcoholic" "fatty" be 61% 66% respondents, Steatotic disease chosen an overarching term encompass various aetiologies steatosis. steatohepatitis important pathophysiological concept should retained. replace metabolic dysfunction-associated steatotic (MASLD). There definition include presence at least 1 5 cardiometabolic risk factors. Those with no parameters known cause deemed have cryptogenic disease. new category, outside pure disease, termed alcohol related/associated (MetALD), selected describe those who consume greater amounts per week (140-350 g/wk 210-420 for females males, respectively). criteria widely supported non-stigmatising, can improve awareness identification.

Language: Английский

---

Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2020, Volume and Issue: 18(4), P. 223 - 238

Published: Dec. 21, 2020

Language: Английский

---

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Hepatology, Journal Year: 2023, Volume and Issue: 78(6), P. 1966 - 1986

Published: June 22, 2023

The principal limitations of the terms NAFLD and NASH are reliance on exclusionary confounder use potentially stigmatising language. This study set out to determine if content experts patient advocates were in favor a change nomenclature and/or definition. A modified Delphi process was led by three large pan-national liver associations. consensus defined priori as supermajority (67%) vote. An independent committee external made final recommendation acronym its diagnostic criteria. total 236 panelists from 56 countries participated 4 online surveys 2 hybrid meetings. Response rates across survey rounds 87%, 83%, 78%, respectively. Seventy-four percent respondents felt that current sufficiently flawed consider name change. “nonalcoholic” “fatty” be 61% 66% respondents, Steatotic disease chosen an overarching term encompass various aetiologies steatosis. steatohepatitis important pathophysiological concept should retained. replace metabolic dysfunction–associated steatotic disease. There definition include presence at least 1 5 cardiometabolic risk factors. Those with no parameters known cause deemed have cryptogenic new category, outside pure disease, termed alcohol related/associated (MetALD), selected describe those who consume greater amounts per week (140–350 g/wk 210–420 for females males, respectively). criteria widely supported nonstigmatising, can improve awareness identification.

Language: Английский

---

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings

Endocrine Practice, Journal Year: 2022, Volume and Issue: 28(5), P. 528 - 562

Published: May 1, 2022

Language: Английский

---

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Annals of Hepatology, Journal Year: 2023, Volume and Issue: 29(1), P. 101133 - 101133

Published: June 24, 2023

The principal limitations of the terms NAFLD and NASH are reliance on exclusionary confounder use potentially stigmatising language. This study set out to determine if content experts patient advocates were in favor a change nomenclature and/or definition. A modified Delphi process was led by three large pan-national liver associations. consensus defined priori as supermajority (67%) vote. An independent committee external made final recommendation acronym its diagnostic criteria. total 236 panelists from 56 countries participated 4 online surveys 2 hybrid meetings. Response rates across survey rounds 87%, 83%, 78%, respectively. Seventy-four percent respondents felt that current sufficiently flawed consider name change. "nonalcoholic" "fatty" be 61% 66% respondents, Steatotic disease chosen an overarching term encompass various aetiologies steatosis. steatohepatitis important pathophysiological concept should retained. replace metabolic dysfunction-associated steatotic disease. There definition include presence at least 1 5 cardiometabolic risk factors. Those with no parameters known cause deemed have cryptogenic new category, outside pure disease, termed alcohol related/associated (MetALD), selected describe those who consume greater amounts per week (140-350 g/wk 210-420 for females males, respectively). criteria widely supported nonstigmatising, can improve awareness identification.

Language: Английский

---

Advancing the global public health agenda for NAFLD: a consensus statement

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2021, Volume and Issue: 19(1), P. 60 - 78

Published: Oct. 27, 2021

Language: Английский

---

Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach

˜The œLancet. Gastroenterology & hepatology, Journal Year: 2021, Volume and Issue: 6(7), P. 578 - 588

Published: May 4, 2021

Language: Английский

---

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review

Journal of Obesity & Metabolic Syndrome, Journal Year: 2023, Volume and Issue: 32(3), P. 197 - 213

Published: Sept. 13, 2023

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the latest term for associated with metabolic syndrome. MASLD most common cause of chronic and leading liver-related morbidity mortality. It important that all stakeholders be involved in tackling public health threat obesity obesity-related diseases, including MASLD. A simple clear assessment referral pathway using non-invasive tests essential to ensure patients severe are identified referred specialist care, while less remain primary where they best managed. While lifestyle intervention cornerstone management MASLD, cardiovascular risk must properly assessed managed because No pharmacological agent has been approved treatment but novel anti-hyperglycemic drugs appear have benefit. Medications used diabetes other conditions may need adjusted as progresses cirrhosis, especially decompensated cirrhosis. Based on tests, concepts compensated advanced clinically significant portal hypertension provide a practical approach stratifying according complications can help manage such patients. Finally, prevention sarcopenia should considered

Language: Английский

---

MAFLD: How is it different from NAFLD?

Clinical and Molecular Hepatology, Journal Year: 2022, Volume and Issue: 29(Suppl), P. S17 - S31

Published: Nov. 29, 2022

“Metabolic dysfunction-associated fatty liver disease (MAFLD)” is the term suggested in 2020 to refer related systemic metabolic dysregulation. The name change from nonalcoholic (NAFLD) MAFLD comes with a simple set of criteria enable easy diagnosis at bedside for general medical community, including primary care physicians. Since introduction term, there have been key areas which superiority over traditional NAFLD terminology has demonstrated, risk and extrahepatic mortality, associations, identifying high-risk individuals. Additionally, adopted by number leading pan-national national societies due its concise diagnostic criterion, removal requirement exclude concomitant diseases, reduction stigma associated this condition. current article explores differences between diagnosis, benefit, some potential limitations, how opened up new fields research.

Language: Английский

---

Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement

˜The œLancet. Gastroenterology & hepatology, Journal Year: 2021, Volume and Issue: 6(10), P. 864 - 873

Published: Aug. 6, 2021

Language: Английский

---